SAN DIEGO, Sept. 22, 2008 (GLOBE NEWSWIRE) -- Asphelia Pharmaceuticals, a privately held, clinical-stage company focused on the development of novel therapeutics for the treatment of immunological disorders, will be presenting at a number of international conferences this Fall, including:
* BioContact Quebec City (Canada), a Biopharmaceutical
Partnership Symposium on Wednesday, October 1st at 3PM (Salle
Jacques-Cartier)
* BioNetwork '08 (Laguna Beach, CA), the 6th Annual
Pharmaceutical-Biotech Partnering Conference on Tuesday,
October 7th at 2:15PM during the Inflammatory Disease
Partnering Primer Session
* BioPartnering Europe (London, United Kingdom) on Tuesday,
October 14th at 10:15AM (Podium Presentation Stream 1)
* BIOCOM 3rd Annual Investor Conference (La Jolla, CA),
October 27 at 4:00 p.m. at The Aventine Ballroom, Room B
* YoungStartups 2008 Life Sciences & Healthcare Venture
Summit on Thursday, October 30th in New York City at
The Digital Sandbox Network (55 Broad Street - 4th Floor)
Francois-Xavier Frapaise MD, President and CEO of Asphelia, will provide an overview of Asphelia's core-assets, including a Trichuris suis ova-based therapy (ASP 1002) and an oral integrin and adhesion molecule antagonist (ASP 2002). Dr. Frapaise's presentation will be focused on the immunomodulating effects of Helminths and the use of this novel therapeutic approach in the treatment of immunological disorders such as Crohn's Disease, Multiple Sclerosis, as well as allergic conditions. The Helminths technology is currently being assessed in a number of clinical studies being conducted globally. Dr. Frapaise will also be available for individual meetings before and after his presentations.
About Asphelia Pharmaceuticals, Inc.
Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelia's primary focus lies in its development of therapies targeting Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including multiple sclerosis and asthma. Asphelia's lead compounds target the cause of Inflammatory Bowel Disease, not just its symptoms, in an effort to change the course of the diseases and allow patients new freedoms. Asphelia's immunotherapeutics seek to provide patients with safer, more effective and more convenient care.